Johanne Lade-Keller

Dr. Johanne Lade-Keller

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
JLJohanne Lade-Keller
Johanne Lade-Keller
KRKirsten M. Rømer
Kirsten M. Rømer
PGPer Guldberg
Per Guldberg
RRRikke Riber-Hansen
Rikke Riber-Hansen
LHLise Lotte Hansen
Lise Lotte Hansen
LKLasse Kristensen
Lasse Kristensen

21 November 2022 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
ETEa Maria Tønning Tønnesen
Ea Maria Tønning Tønnesen
MSMagnus Stougaard
Magnus Stougaard
PMPeter Meldgaard
Peter Meldgaard
JLJohanne Lade-Keller
Johanne Lade-Keller
Aims: The aim of this study was to investigate the association between oncogenic alterations and programmed cell death ligand 1 (PD-L1) expression in lung adenocarcinomas, as well as the prognostic value of KRAS and/or TP53 mutations in patients treated with immunotherapy. Methods: This study is a retrospective cohort study of 519 patients with lung adenocarcinomas analysed for mutations and PD-L1 expression. Data were collected from electronic pathology record system, next-generation sequencing system, and clinical databases. Association between mutations and PD-L1 expression was investigated, as well as survival statistics of the 65 patients treated with immunotherapy. Results: 41% of the samples contained a KRAS mutation, predominantly together with mutations in TP53 (41%) or STK11 (10%). Higher expression of PD-L1 was seen among patients with KRAS mutations (p=0.002) and EGFR wild type (p=0.006). For patients treated with immunotherapy, there was no statistically significant difference for overall survival (OS) and progression-free survival (PFS) according to KRAS mutation status, TP53 mutation status or PD-L1 expression. The HR for concomitant mutations in TP53 and KRAS was 0.78 (95% CI 0.62 to 0.99) for OS and 0.43 (0.21 to 0.88) for PFS. Furthermore, concomitant TP53 and KRAS mutations predicted a better PFS (p=0.015) and OS (p=0.029) compared with no mutations or a single mutation in either TP53 or KRAS . Conclusion: Mutations in TP53 together with KRAS may serve as a potential biomarker for survival benefits with immunotherapy.

1 October 2021 in Pathology - Research and Practice
Verified
Journal Article
Open access
DÖDemet Özcan
Demet Özcan
JLJohanne Lade-Keller
Johanne Lade-Keller
TTTrine Tramm
Trine Tramm
Background: Programmed-cell-death-ligand 1 (PD-L1) inhibitor treatment is approved for metastatic/recurrent, PD-L1 positive, triple-negative breast cancer (TNBC) and solid tumors with mismatch repair (MMR) defect regardless of PD-L1 status. The analytical validity of PD-L1 has been questioned and adding evaluation of tumor infiltrating lymphocytes (TILs) may identify patients likely to respond to immunotherapy. We investigated the association between MMR-deficiency and PD-L1 in TNBC; aiming to identify PD-L1 negative, TNBC patients that may be candidates for anti-PD-L1 immunotherapy. Methodology: Paraffin-embedded tumor material from 44 TNBC patients was included. In 38 cases, immunohistochemical-staining acute accent s on whole-slide sections were successful for all four MMR proteins (MSH2, MSH6, MLH1 and PMS2) and PD-L1 in 36 cases. MMR-status was categorized as positive (pMMR), heterogeneous (hMMR) or deficient (dMMR). Tumor-infiltrating lymphocytes (TILs) were evaluated on H&E sections. Results: MMR stainings showed substantial intratumor heterogeneity. Four of 38 cases (11%) were recorded as dMMR with loss of > 1 MMR-protein and 19 cases (50%) showed heterogeneous expression or partial loss (hMMR) of > 1 MMR-protein. Three of 22 PD-L1 negative cases were dMMR (14%) and ten cases hMMR (45%). 16 of 22 PD-L1 negative cases (73%) showed high TILs. Conclusions: A substantial proportion of PD-L1 negative, TNBC patients showed complete/partial loss of MMR and/or high TILs indicating that supplementing PD-L1 examination with these biomarkers may identify TNBCpatients that may be selected for immunotherapy.

8 November 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
LNLine B Nielsen
Line B Nielsen
NDNina Dabrosin
Nina Dabrosin
KSKaren Sloth
Karen Sloth
MBMarie L Bønnelykke–Behrndtz
Marie L Bønnelykke–Behrndtz
TSTorben Steiniche
Torben Steiniche
JLJohanne Lade-Keller
Johanne Lade-Keller

22 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TLTrine Larsen
Trine Larsen
NDNina Dybdal
Nina Dybdal
TDTina F. Daugaard
Tina F. Daugaard
JLJohanne Lade-Keller
Johanne Lade-Keller
LLLin Lin
Lin Lin
ANAnders Lade Nielsen
Anders Lade Nielsen
Immunotherapy targeting the interaction between programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) is a treatment option for patients with non-small-cell lung cancer (NSCLC). The expression of PD-L1 by the NSCLC cells determines treatment effectiveness, but the relationship between PD-L1 DNA methylation and expression has not been clearly described. We investigated PD-L1 DNA methylation, mRNA expression, and protein expression in NSCLC cell lines and tumor biopsies. We used clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) to modify PD-L1 genetic contexts and endonuclease deficient Cas9 (dCas9) fusions with ten-eleven translocation methylcytosine dioxygenase 1 (TET1) and DNA (cytosine-5)-methyltransferase 3A (DNMT3A) to manipulate PD-L1 DNA methylation. In NSCLC cell lines, we identified specific PD-L1 CpG sites with methylation levels inversely correlated with PD-L1 mRNA expression. However, inducing PD-L1 mRNA expression with interferon-γ did not decrease the methylation level for these CpG sites, and using CRISPR-Cas9, we found that the CpG sites did not directly confer a negative regulation. dCas9-TET1 and dCas9-DNMT3A could induce PD-L1 hypo- and hyper-methylation, respectively, with the latter conferring a decrease in expression showing the functional impact of methylation. In NSCLC biopsies, the inverse correlation between the methylation and expression of PD-L1 was weak. We conclude that there is a regulatory link between PD-L1 DNA methylation and expression. However, since these measures are weakly associated, this study highlights the need for further research before PD-L1 DNA methylation can be implemented as a biomarker and drug target for measures to improve the effectiveness of PD-1/PD-L1 immunotherapy in NSCLC.

1 October 2018 in Melanoma Research
Verified
Journal Article
Closed access
JLJohanne Lade-Keller
Johanne Lade-Keller
SYSakineh Yuusufi
Sakineh Yuusufi
RRRikke Riber-Hansen
Rikke Riber-Hansen
TSTorben Steiniche
Torben Steiniche
MSMagnus Stougaard
Magnus Stougaard
The aims of this study were to assess the prognostic potential of solar elastosis grading and telomerase reverse transcriptase (TERT) promoter mutations (TERTpmut) in melanoma and to evaluate whether an association between solar elastosis and TERTpmut exists. Solar elastosis in the dermis was evaluated in hematoxylin and eosin-stained whole slides from 486 malignant melanomas. Pyrosequencing was used to detect TERTpmut in 189 samples. There was no association between solar elastosis and TERTpmut (P=0.3). Severe elastosis was associated with older age (P<0.0001), ulceration (P=0.03), and location in the head/neck region (P<0.0001). The absence of elastosis was associated with younger age (P<0.0001), benign nevus remnants (P=0.001), and a positive BRAF V600E expression (P<0.0001). Severe elastosis predicted a worse relapse-free survival (hazard ratio: 2.18; 95% confidence interval: 1.30–3.64; P=0.003). However, it was not independent of age. TERTpmut was not associated with any adverse prognostic or clinicopathological outcome, nor any mitogen-activated protein kinase-related protein expressions. However, at a cutoff corresponding to the sensitivity of Sanger sequencing, TERTpmut predicted melanoma-specific death independently of age, and was associated with Breslow thickness, ulceration, tumor stage at diagnosis, BRAF V600E oncoprotein, and absence of p16 expression. In conclusion, TERTpmut were not related to severe elastosis and may thus be triggered by both chronic and acute intermittent sun exposure, the latter not visible on ordinary hematoxylin and eosin-stained slides. Neither TERTpmut nor severe elastosis predicted an adverse outcome in melanoma. An absence of elastosis was seen in younger melanoma patients and may be used to select those melanomas originating in a nevus, which often harbors a BRAF mutation.